Divarasib beats adagrasib and sotorasib in the 2nd line treatment of KRAS G12C mutated NSCLC. This sets a new standard for now, but I’m hopeful that this is just the first of many

Urs Weber MD· @UrsWeberMD · X·2026-10-26 02:44· 15 hours agoScore70

Body · original

Divarasib beats adagrasib and sotorasib in the 2nd line treatment of KRAS G12C mutated NSCLC. This sets a new standard for now, but I’m hopeful that this is just the first of many positive trials in KRAS mutated NSCLC in the coming years. @KRASKickers @myESMO #ESMO26

21 views · 1 like · 1 repost · 0 replies

Conference abstracts

2551TIPNCT07541170 NCT07541170 NCT07541170matched by NSCLC, early stage

Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer

https://esmocongress.esmo.org

引用@

Presented at #ESMO26: In patients with previously treated advanced non–small-cell lung cancer with a 𝘒𝘙𝘈𝘚 G12C mutation, median progression-free survival was 9.8 months with the KRAS G12C inhibitor divarasib and 5.7 months with sotorasib or adagrasib. Full phase 3 Krascendo 1 trial results: https://nej.md/4BiCvbk @myESMO

在 X 查看被引用的帖子

Source: Urs Weber MD · x.com